Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear
FDA Priority Review Granted
Executive Summary
With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear.
You may also be interested in...
Takeda Takes Collaborative, Educational Approach In Thai Dengue Initiative
As it looks to roll out its new dengue vaccine globally, Takeda will work with Kao’s Thai subsidiary on education and prevention activities in Bangkok, later expanding these to wider areas of Thailand, in the first such local collaboration by the private sector.
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
Global First Approval For Takeda's Dengue Vaccine, In Indonesia
Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders.